One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
This article was originally published in The Pink Sheet Daily
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.
You may also be interested in...
The agency will seek advisory panel input Nov. 3-4 on options for facilitating trials in community-, hospital- and ventilator-acquired pneumonia.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.